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Abstract
Atypical apocrine adenosis (AAA) is a benign lesion of the breast that is identified more frequently today
than in the past when it was considered a rare diagnosis and commonly misdiagnosed as other malignant
lesions of the breast. AAA is defined as the presence of apocrine cytology in a recognisable lobular unit
associated with sclerosing adenosis. We present a case of an incidental finding of AAA and discuss
diagnostic challenges and their implications on clinical management.
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Introduction
Some breast lesions are associated with apocrine phenotype features, such as atypical apocrine adenosis
(AAA), apocrine ductal carcinoma in situ (DCIS), and invasive carcinoma with apocrine features [1].
AAA is a rare benign breast lesion and should not be regarded as a direct histologic precursor to invasive
breast carcinoma. The presence of significant cytological atypical changes in the breast apocrine cells (e.g.,
nuclear enlargement, prominent/multiple nucleoli, and hyperchromasia) is known as apocrine atypia. Breast
AAA is defined as the presence of apocrine cytology in a recognisable breast lobular unit associated with
sclerosing adenosis [2].
Case Presentation
A 54-year-old woman underwent coronary angiogram computed tomography (CT) for chest pain. The CT
revealed only an incidental right breast small nodule (Figure 1). Her past medical history and family history
were unremarkable. The findings of her breast examination were also unremarkable.
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FIGURE 1: Chest computed tomography showing a small lesion in the
right breast
Her mammogram (Figure 2) revealed a well-defined soft tissue nodule measuring 11 mm in the medial part
of the right breast (Breast Imaging, Reporting, and Data System [BI-RADS] grade M2). Right breast
ultrasonography (Figure 3) showed a lobulated hypoechoic lesion with slightly ill-defined margins in places.
Appearances were indeterminate (BI-RADS grade U3).
FIGURE 2: Mammogram showing the right breast lesion
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FIGURE 3: Right breast ultrasound showing the right breast lesion
Core biopsy of breast tissue showed tightly packed acini with the epithelium of apocrine type exhibiting
nuclear pleomorphism. The lesional cells were large with abundant eosinophilic cytoplasm and large
vesicular nuclei, with prominent eosinophilic nucleoli and formed nests and irregular ducts within a fibrous
stroma. The specimen had focal cribriform and solid architecture. Immunohistochemistry studies revealed
that the cells are strongly and diffusely positive for gross cystic disease fluid protein (GCDFP)-15 and
negative for oestrogen receptors. With p63 and smooth muscle actin (SMA) stains, the myoepithelial cells
appeared mostly preserved with a degree of loss in the solid areas. These features were consistent with AAA.
The lump was removed surgically with wire-guided localisation (Figure 4), and the postoperative histology
confirmed completely excised AAA (Figure 5). After surgery, the patient was advised to continue with the
Breast National Screening Programme.
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FIGURE 4: Wire-guided excision biopsy of the lesion
FIGURE 5: Histopathologic picture of the lesion demonstrating atypical
apocrine adenosis. The epithelium is of apocrine type with nuclear
pleomorphism in closely packed acini
Discussion
Exocrine glands
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The exocrine gland classification is based on how the secretory cells produce their secretions (Figure 6).
FIGURE 6: Exocrine glands
Merocrine glands
The merocrine (eccrine) gland secretions are excreted by exocytosis in the lumen of a duct system (Figure 7).
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FIGURE 7: Merocrine glands
Holocrine glands
The holocrine gland secretions are initially produced in the cell cytoplasm, then the cell membrane
ruptures, and the entire cell disintegrates to release its substance (Figure 8).
FIGURE 8: Holocrine cells
Apocrine glands
The apocrine gland cells bud their secretions off through the plasma membrane, producing extracellular
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membrane-bound vesicles (Figure 9).
FIGURE 9: Apocrine cells
Histologically, apocrine cells have an abundant eosinophilic or granular cytoplasm, and their nucleus
contains distinct nucleoli in its round vesicular form [3].
Apocrine cells are divided into two categories. Type A apocrine cells have apical luminal blebbing or
snouting and distinctive cell membranes. The apical portion of the cell contains coarse birefringent
granules. The nuclei have globoid shape, often pale with one or two prominent nucleoli. A supranuclear
iron-containing brown pigmented vacuole may be present [4].
Type B apocrine cells have a distinctly foamy cytoplasm, which contains small vacuoles that may coalesce
and show lipofuscin pigment in their cytoplasm. The nuclei are usually located centrally and possess similar
characteristics of type A apocrine cells [4].
The anatomical sites of the apocrine cells are axillary and groin sweat glands and the breast periareolar
apocrine glands. They are also present in the perianal region, labia majora in women, and the scrotum and
prepuce in men [5].
Histological characters of AAA
The term apocrine adenosis describes sclerosing adenosis present in the breast apocrine cells. However, in
the presence of significant cytological atypical changes in the apocrine cells, such as thre-fold nuclear
enlargement, prominent/multiple nucleoli, and hyperchromasia, the term apocrine atypia is used. When
apocrine adenosis and apocrine atypia are superimposed, AAA is diagnosed [1]. AAA is a benign breast lesion
and should not be regarded as a direct histologic precursor to breast carcinoma [6].
Radiological features
The mammogram may reveal the abnormality with or without amorphous or coarse heterogeneous
calcifications. On ultrasonography, AAA may appear as irregular or circumscribed lesion. The magnetic
resonance image may depict persistently enhancing focus [7].
Atypical apocrine metaplasia was not a common diagnosis in the past, and most of those diagnoses were
based on findings in specimens. However, given current advancements in breast imaging techniques and the
increased use of Tru-Cut® biopsy (Merit Medical, South Jordan, UT), the diagnosis of atypical apocrine
metaplasia is encountered more often, even daily in large breast centres.
Immunohistochemistry
The absence of female sex hormone biomarkers (oestrogen and progesterone) and the presence of androgen
receptor and GCDFP-15 confirm the diagnosis of apocrine adenosis with atypia [1]. Hematoxylin and eosin
staining methods are mainly used for specimen study. It is important to have an accurate study of the
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specimens to avoid unnecessary surgical procedures.
GCDFP-15 is a glycoprotein originally isolated in the human breast. It is used as a specific
immunohistochemical diagnostic marker for apocrine differentiation, especially in tumours originating in
the breast (including apocrine carcinoma of the breast) [8-10].
Apocrine cells usually lack oestrogen and progesterone receptors, but they are positive for androgen
receptors [1]. Our case specimen was negative for oestrogen receptors.
Cytokeratin (CK) 5 is a basic (type II) cytokeratin useful for detecting benign breast proliferation [11]. CK5
expression is variable in breast AAA [1]. It can also be detected in the basal-like subtype of invasive ductal
carcinoma of the breast [10,12].
Transformation-related protein 63 (P63) is a protein encoded by the TP63 human gene. This marker is used
for squamous differentiation, and its mutation is associated with Li-Fraumeni syndrome. It differentiates
malignant conditions, which are often p53 positive, from reactive and metaplastic conditions, which are
usually p53 negative [8,10]. P63 may show focal staining in AAA [2,13].
SMA is a marker found in stromal myofibroblastic cells, and it is used to identify myoepithelial cells in
normal, neoplastic, or diseased breast [14,15].
Differential diagnosis and risk of malignancy
In 1990, Tavassoli and Norris suggested using the phrase atypical apocrine metaplasia, when a healthy
breast gland is replaced by one layer of markedly pleomorphic apocrine cells with a threefold variation in
nuclear size [16]. This is known as benign lesions; however, the risk of breast cancer is controversial. Breast
AAA is of great importance to differentiate the histological picture of apocrine adenosis with atypia from
cancerous and precancerous lesions as it may be misinterpreted as carcinoma. Breast AAA needs to be
differentiated from low-grade apocrine DCIS; most of the low-grade apocrine DCIS have moderate
pleomorphic nuclei and multiple nucleoli in addition to occasional large multinucleate cells [17].
Sometimes, breast pleomorphic lobular carcinoma in situ (PLCI) involves sclerosing adenosis. PLCI cells
exhibit a significant degree of nuclear pleomorphism compared with classic lobular carcinoma in situ with
prominent nucleoli, and their staining is positive for GCDFP-15 [18]. Breast AAA may be mistakenly
diagnosed as breast invasive carcinoma due to the presence of enlarged cells and stromal distortion [1]
(Table 1).
Differential Diagnosis
Breast atypical ductal hyperplasia
Breast pleomorphic lobular carcinoma in situ
Invasive ductal carcinoma
Low-grade apocrine DCIS
Breast invasive apocrine carcinoma
TABLE 1: Differential diagnosis of breast atypical apocrine adenosis
DCIS, ductal carcinoma in situ
There is no direct link between AAA and malignancy, and the data from long-term follow-up studies of open
biopsies suggest that AAA is not a high-risk or precursor lesion [19].
Fuehrer et al. from Mayo clinic published a cohort study in 2011, which included 37 women found to have
apocrine adenosis with metaplasia in biopsy specimens [6]. Of the 37 patients, only three developed invasive
ductal carcinoma or DCIS with a relative risk of 8% for cancer. This relative risk is similar to the general
population relative risk for breast cancer. Hence, it was concluded that AAA is a benign, non-aggressive
disease and does not progress into a malignant lesion.
Seidman et al. published observations about AAA and concluded that AAA confers an increased risk of
developing breast carcinoma in women older than age 60 years, and the risk in younger women is probably
low [20]. They advocated conservative management; however, the modality or the interval of follow-up was
2020 Khan et al. Cureus 12(6): e8624. DOI 10.7759/cureus.8624 8 of 10
not specified.
Conclusions
Apocrine change is becoming a frequent finding in breast specimens due to the increase in the number of
the performed biopsies. Atypical apocrine features in sclerosing abnormality may be misdiagnosed as
invasive carcinoma, and accurate diagnosis helps to avoid unnecessary overtreatment. While we believe it is
a benign feature of the breast, further research is needed to set the guidelines for management and follow-
up of patients with AAA.
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